TNKASE (tenecteplase) / Roche, Boehringer Ingelheim 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...3456789101112131415»
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    Clinical, Review, Journal:  Diagnosis and Treatment of Acute Coronary Syndromes: A Review. (Pubmed Central) -  Feb 22, 2022   
    For patients with STEMI, coronary catheterization and PCI within 2 hours of presentation reduces mortality, with fibrinolytic therapy reserved for patients without access to immediate PCI. For high-risk patients with NSTE-ACS without contraindications, prompt invasive coronary angiography followed by percutaneous or surgical revascularization is associated with lower rates of death.
  • ||||||||||  Meforex (recombinant human TNK tissue-type plasminogen activator) / CSPC Pharma
    Trial completion date:  BRIDGE-TNK: Endovascular Treatment With Versus Without Intravenous rhTNK-tPA in Stroke (clinicaltrials.gov) -  Feb 4, 2022   
    P2/3,  N=586, Not yet recruiting, 
    As this study was limited by a small sample size, larger confirmatory studies are needed. Trial completion date: Dec 2025 --> Apr 2026
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    Enrollment closed, Trial primary completion date:  AcTQuICR: Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke (clinicaltrials.gov) -  Feb 1, 2022   
    P3,  N=1600, Active, not recruiting, 
    Trial completion date: Dec 2025 --> Apr 2026 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2022 --> May 2022
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    MCCONNELL’S SIGN AS INITIAL PRESENTATION OF RECURRENT COVID-19 INFECTION (eAbstract site) -  Jan 28, 2022 - Abstract #ACC2022ACC_6727;    
    Obstructive shock in the setting of COVID 19 is associated with a high mortality, and repeat infection with COVID 19 may increase the probability of eliciting such critical sequelae. Early recognition of McConnell’s sign on TTE followed by prompt treatment to reduce clot burden and underlying COVID 19 infection is lifesaving.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    THERAPEUTIC APPROACH TO STEMI SECONDARY TO ESSENTIAL THROMBOCYTOSIS (Poster Hall_Hall C) -  Jan 28, 2022 - Abstract #ACC2022ACC_3973;    
    Due to time constraints patient initially received Tenecteplase, and after 55 min was transferred to the cardiac catheterization lab...Anticoagulation with bivalirudin and DAPT with ticagrelor and aspirin was utilized during the procedure... This case shows the importance of seeking alternate etiologies, including thrombocytosis, to an acute MI especially in the younger population without clear CAD risk factors.Treatment of such myocardial infarctions with angioplasty and thrombectomy without use of stents, with close monitoring and follow up has been shown to be successful.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    SIMULTANEOUS PULMONARY EMBOLISM AND PARADOXICAL ST ELEVATION MYOCARDIAL INFARCTION IN THE PRESENCE OF A PATENT FORAMEN OVALE (Complex Clinical Cases Moderated Poster Theater 1_Hall C) -  Jan 28, 2022 - Abstract #ACC2022ACC_273;    
    ECG showed ST-segment elevation in anterior and inferior leads.Decision‐making: Once STEMI was diagnosed, she received Tenecteplase and was transferred to a PCI center... The similar presentation of these two cardioembolic conditions make the differential diagnosis very challenging, hence, suspicion of PFO is essential.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    Retrospective data, Journal:  A retrospective analysis of fibrinolytic and adjunctive antithrombotic treatment during cardiopulmonary resuscitation. (Pubmed Central) -  Jan 27, 2022   
    Four of five patients who were discharged from hospital had received additional antithrombotic treatment during CPR and were in appropriate neurological status (CPC 1). Considering the small sample size in this retrospective study, the argument may be still be made that fibrinolytic and adjunctive antithrombotic treatment during cardiopulmonary resuscitation in out-of-hospital cardiac arrest of assumed cardiac origin may increase the chances for survival.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    Trial completion date, Trial primary completion date:  ORIGINAL: A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity (clinicaltrials.gov) -  Jan 25, 2022   
    P3,  N=800, Recruiting, 
    Considering the small sample size in this retrospective study, the argument may be still be made that fibrinolytic and adjunctive antithrombotic treatment during cardiopulmonary resuscitation in out-of-hospital cardiac arrest of assumed cardiac origin may increase the chances for survival. Trial completion date: May 2023 --> Dec 2022 | Trial primary completion date: May 2023 --> Dec 2022
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    Journal:  Low-cost alternatives for the management of acute ischemic stroke in low and middle-income countries. (Pubmed Central) -  Jan 8, 2022   
    Acute ischemic stroke (AIS) patients arriving within a suitable time frame are treated with recanalization therapy i.e. intravenous thrombolysis (IVT) with alteplase and/or mechanical thrombectomy (MT)...In general, the current treatment guidelines for AIS are not very useful in LMICs because of cost-related issues among several other factors. In this editorial, we discuss evidence for alternative treatment strategies that can help tackle the rising epidemic of AIS in poor countries by improvising on existing clinical guidelines and seeking alternative treatment regimens.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    Review, Journal:  Early Experience With Tenecteplase at a Comprehensive Stroke Center. (Pubmed Central) -  Jan 7, 2022   
    A case is presented to illustrate the successful implementation of this new process. Development of our protocol is discussed in detail to enable other centers to create their own clinical pathways for thrombolytic treatment of acute ischemic stroke using tenecteplase.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    Clinical, Review, Journal:  Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review. (Pubmed Central) -  Jan 6, 2022   
    Development of our protocol is discussed in detail to enable other centers to create their own clinical pathways for thrombolytic treatment of acute ischemic stroke using tenecteplase. The available evidence suggests that tenecteplase appears to be a better thrombolytic agent for acute ischemic stroke when compared to alteplase.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    Reduced Hospital Costs For Ischemic Stroke Treated With Tenecteplase (Hall B2, Poster Hall; Board No. MP52) -  Dec 21, 2021 - Abstract #ISC2022ISC_426;    
    An expanded analysis including other markets that switched to TNK in our national hospital system is in progress. If the current results generalize, the savings potential with a switch to TNK as the standard could be substantial for the health care system.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    Tenecteplase For The Treatment Of Acute Ischemic Stroke: A Systematic Review And Meta-analysis Of Real World Evidence (Hall B2, Poster Hall; Board No. MP4) -  Dec 21, 2021 - Abstract #ISC2022ISC_375;    
    Larger prospective ‘real-life’ studies are required to validate our findings. Real world evidence suggests that tenecteplase has a comparable efficacy and safety profile to alteplase for the treatment of AIS, while being possibly superior in achieving successful reperfusion and early neurological improvement.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    Safety Of Tenecteplase And Alteplase In Tandem Lesion Stroke: A Pooled Analysis Of The Extend-IA TNK Trials (Riverside Room R06-R09) -  Dec 21, 2021 - Abstract #ISC2022ISC_343;    
    Although patients with TL in the anterior circulation were at higher risk of hemorrhagic complications, these did not significantly differ between the TNK and tPA groups. A numeric increase in bleeding with TNK was not accompanied by an increase in mortality or worse functional outcome.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    Magnetically Enhanced Diffusion (MED) Of Intravenous Thrombolytics Decreases Thrombus Leading To Accelerated Reperfusion (Hall B2, Poster Hall; Board No. P148) -  Dec 21, 2021 - Abstract #ISC2022ISC_221;    
    rtPA (Activase, 1mg/kg, Genentech) was infused IV over 1h or Tenecteplase (TNK, 0.3-0.9mg/kg, Genentech) was injected IV as a bolus...Thus significant acceleration of lysis and reduction in clot weight occurs after treatment with MicroBeads plus lytic compared to lytic alone. This approach may enhance reperfusion and decrease infarction during stroke treated by either lytic alone or lytic + thrombectomy leading to improved outcomes.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    Tenecteplase Is Safe And Efficacious In Telestroke Patients With Confirmed Large Vessel Occlusions (Room 208-210) -  Dec 21, 2021 - Abstract #ISC2022ISC_44;    
    There were no differences reported between thrombolysis groups and DIO, p = 0.63. Conclusion Telestroke patients presenting with confirmed LVO and treated with IV tenecteplase were found to have better 90 day outcomes compared to patients treated with IV alteplase, without increased complication rates.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    Steps To An Early And Successful Adoption Of Iv Tenecteplase By A Large Integrated Medical System (Room 206-207) -  Dec 21, 2021 - Abstract #ISC2022ISC_13;    
    Tenecteplase has been shown to be safe and feasible as a first line thrombolytic within our organization. Strong nurse and physician leads, as well as thoughtful and inclusive implementation steps were key in the successful adoption of this system-wide change.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    Journal:  Tenecteplase for Acute Ischemic Stroke Treatment. (Pubmed Central) -  Dec 16, 2021   
    Further phase 3 studies are in progress comparing rt-PA with TNK for acute ischemic stroke during the first 4.5 hours. Studies are also in progress to evaluate the use of TNK for extended applications, such as wake-up stroke.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    Journal:  Should Tenecteplase Replace Alteplase for Acute Thrombolysis? (Pubmed Central) -  Dec 16, 2021   
    Studies are also in progress to evaluate the use of TNK for extended applications, such as wake-up stroke. No abstract available
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    Trial completion, Enrollment change, Trial completion date:  TASTEa: Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance (clinicaltrials.gov) -  Dec 8, 2021   
    P2,  N=104, Completed, 
    Routine use of tenecteplase for stroke thrombolysis was feasible and had comparable safety profile and outcome to alteplase. Recruiting --> Completed | N=80 --> 104 | Trial completion date: Mar 2022 --> Nov 2021